More News

Balance Ophthalmics Announces 2026 Medicare Pricing for FSYX Pump and Goggles

Balance Ophthalmics reported Aug. 18 that regulators had set 2026 Medicare payment amounts for the FSYX Ocular Pressure Adjusting Pump (OPAP) and associated goggles, effective Oct. 1. The FSYX pump...

US FDA Gives Green Light to Trial of Ciliatech’s Intercil Uveal Spacer for Glaucoma

France’s Ciliatech announced Sept. 8 that the US FDA had signed off on its investigational device exemption (IDE) submission, allowing the company to proceed with a feasibility study of its Interci...

US FDA Accepts BLA for Nanoscope’s Optogenetic Gene Therapy Candidate in RP

Nanoscope Therapeutics announced Sept. 9 that the US FDA had accepted for review its biologics license application (BLA) for Mogenry, an optogenetic gene therapy candidate designed to restore visio...

Surrozen Submits IND Application for Dual-Acting SZN-8141 in DME

Surrozen announced Sept. 8 that it had submitted an investigational new drug (IND) application to the US FDA to launch a clinical trial of SZN-8141, a bifunctional Wnt agonist and vascular endothel...

Chinese Regulators Accept NDA for Glaucoma Drop from Nicox, Ocumension

France’s Nicox and partner Ocumension Therapeutics, of China, announced Sept. 11 that China’s National Medical Products Administration (NMPA) had accepted the new drug application (NDA) for NCX 470...

Belite Bio Submits NDA in Japan for Oral Tinlarebant in Stargardt

Belite Bio announced Sept. 8 that it had submitted a new drug application (NDA) for its oral Stargardt treatment candidate, tinlarebant, to Japan’s Ministry of Health, Labour, and Welfare. Tinlareb...

Foundation Fighting Blindness Renames Venture Arm as Gund Vision Fund

The Foundation Fighting Blindness, of Columbia, Maryland, reported Sept. 10 that it had renamed its venture philanthropy arm the Gund Vision Fund. The fund was formerly called the Retinal Degenerat...

Bausch + Lomb Gains CE Marking for SeeLyra Femtosecond Laser

Bausch + Lomb reported Sept. 11 that its SeeLyra next-generation femtosecond laser had gained CE marking. The company said the SeeLyra, built on the Victus platform, is designed to provides surgeon...

Rayner Launches Galaxy Hydrophobic Spiral IOL

UK-based Rayner reported Sept. 7 the launch of its Galaxy Hydrophobic spiral IOL at the 2026 ESCRS congress in London. The lens will be available commercially in the EU in Q4-2026. The original Gal...

Zeiss Announces Launch of AT Lucia Toric 721P

Zeiss Medical Technology reported Sept. 10 that it was launching its AT Lucia Toric 721P IOL at the 2026 ESCRS congress in London. Zeiss, of Germany, described the lens as the world's first hyd...

Oxford Eye Hospital Initiative Cuts IVT Injection Waste and Costs

Britain’s Oxford Eye Hospital reported Aug. 24 that an initiative there to change the way intravitreal (IVT) injections are administered has eliminated tons of associated single-use product waste a...

Alcon’s Clareon Monofocal Lens Gains MDR Certification, Expanded Labeling

Alcon reported Sept. 1 that it had gained MDR certification in the European Union for its Clareon Monofocal enhanced monofocal intraocular lens. The company noted that the hydrophobic acrylic lens ...

UK Government Outlines Measures to Reduce Ophthalmology Waiting Times

The UK government on Aug. 25 outlined initiatives intended to reduce ophthalmology waiting times, address regional disparities, and move more eye care into community and digital settings. Gillian J...

British Company Exonate Rebrands as Foventa Therapeutics

British company Exonate announced Sept. 1 that it had changed its name to Foventa Therapeutics. The company said its new name and motto “Simply Sharper” take inspiration from the fovea, the center ...

European Consortium Studies Gene-Silencing Eye Drops Targeting Corneal Vascularization

Two studies underway at the University of Cologne in Germany will test whether a new class of eye drops silencing the insulin-receptor substrate 1 (IRS1) gene can slow the blood vessel growth that ...

Stem Cell Treatment Improves Vision for Aniridia-Related Keratopathy

Researchers at Moorfields Eye Hospital and the University College of London have developed a collagen scaffold that delivers limbal epithelial and stromal stem cells to improve vision in eyes with ...

University of Virginia Team Uses Nanotechnology to ID New Target for Treating Glaucoma

Researchers at the University of Virginia have used cutting-edge nanotechnology to probe Schlemm’s canal and identify a potential new genetic target to regulate aqueous humor drainage in patients w...

Alcon Launches Unity M Ophthalmic Surgical Microscope

Alcon announced Sept. 3 the initial commercial launch of its Unity M ophthalmic surgical microscope. The company said the microscope, which has received CE marking in Europe and regulatory approval...

X-Cel and Essilor Launch Lunara Orthokeratology Lens

X-Cel Specialty Contacts and Essilor Custom Contacts announced Aug. 31 the US launch of Lunara, a new FDA-approved orthokeratology lens. Orthokeratology, or ortho-k, uses specially designed and fit...

AI Replaces Presurgical Scans in Removal of Sight-Threatening Brain Tumor

The European Medical Journal reported Aug. 28 that artificial intelligence had provided real-time guidance for removal of a vision-threatening brain tumor at University College London Hospital (UCL...

SpyGlass Celebrates Grand Opening of New Irvine, California, Headquarters

SpyGlass Pharma celebrated the grand opening of its new Irvine, California, headquarters on Aug. 27, as the company continues to expand. SpyGlass was initially founded in Irvine in 2019 by Malik Y....

Ophthalmologist Urges Early Intervention in Dry Eye Management to Avoid Surprises

Jason Bacharach, MD, of North Bay Eye Associates in northern California, has a word of advice for ophthalmologists and optometrists. Four words, actually: interventional dry eye management (IDEM). ...

Basketball Topped US Sports Eye Injuries Treated in 2025, Statistics Show

Basketball had the highest rate of sports-related eye injuries treated in the US in 2025, with 5,236 injuries, according to new statistics published Aug. 26 by Prevent Blindness. The Chicago, Illin...

US FDA Asks for Feedback on GenAI Medical Device Regulation

The US FDA took inspiration from the way human clinicians are trained in drafting a proposal for the regulation of medical devices that feature generative artificial intelligence (GenAI), and it’s ...

Kiora Licenses Retinal Candidate to Chong Kun Dang for South Korea

Kiora Pharmaceuticals announced Aug. 10 that it had granted Chong Kun Dang (CKD) Pharmaceutical Corp. development and commercialization rights in South Korea to KIO-301 for the treatment of degener...

Samsara Vision Promotes Jason Herod to President and Chief Executive Officer

Samsara Vision, of Far Hills, New Jersey, announced Sept. 1 that Jason Herod had been promoted to president and chief executive officer. Herod joined Samsara in 2021 and most recently served as chi...

Zeiss Introduces Cataract-Only Version of DORC Eva Nexus

German company Carl Zeiss Meditec introduced on Aug. 27 a dedicated cataract version of the DORC Eva Nexus surgical system. The original Eva Nexus, a dual-function cataract and vitrectomy machine, ...

US FDA Accepts NDA for Glaucoma Drop from Nicox and Kowa, Sets PDUFA Date of April 30, 2027

France’s Nicox announced Aug. 27 that the US FDA had accepted the new drug application (NDA) for NCX 470 (bimatoprost grenod; also known as K-911) and set a Prescription Drug User Fee Act (PDUFA) t...

Bausch + Lomb Advancing Dual-Action Dry Eye Drop, Ocular Surface Pain Candidate

Bausch + Lomb reported Aug. 24 that it would advance two of its topical ocular pipeline candidates based on clinical trial results. The company’s dual-action dry eye drop candidate—combining lifite...

Indigo Light Prevents Myopia Completely in Animal Model, Researchers Find

Vision researchers have found that indigo light prevents myopia completely in a tree shrew model. Their findings were published Aug. 18, 2026, in Cell Reports Medicine. The study’s lead researchers...

Light-Filtering Lenses for Migraine from Avulux Gain US FDA De Novo Marketing Nod

Avulux announced Aug. 24 that its eyeglass lenses had gained US FDA de novo marketing authorization to decrease the impact of light sensitivity in patients ages 12 and older diagnosed with episodic...

Santen Launches Rhopressa Glaucoma Drops in Japan

Santen announced Aug. 17 that it had launched Rhopressa (netarsudil ophthalmic solution) 0.02%, an eye drop targeting glaucoma and ocular hypertension, in Japan. The treatment gained marketing appr...

Japan Grants Orphan Status to Alkeus’ Oral Gildeuretinol for Stargardt

Alkeus Pharmaceuticals announced Aug. 24 that Japan’s Ministry of Health, Labour, and Welfare had granted orphan drug status to gildeuretinol, its oral therapy candidate for Stargardt disease. In J...

Biosimilars, Longer-Acting Treatments Depress Exudative Retinal Pharma Revenue

Total manufacturers’ revenue from pharmaceuticals for exudative retinal diseases are on course to decline for the second year in a row—a first since the introduction of anti-VEGF therapy in 2004. M...

Q2-2026 Ophthalmic Revenue Roundup for STAAR, Lensar, Iridex, and Lenz

STAAR Surgical, of Lake Forest, California, reported Aug. 12 that its Q2-2026 net sales were $93.5 million, a 111 percent increase over $44.3 million in Q2-2025. China sales in Q2-2026 were $52.3 m...

Lupin’s Visufarma Licenses Yuvezzi Presbyopia Drops for Europe, UK

Visufarma, a subsidiary of India-based Lupin Limited, announced Aug. 20 that it had licensed exclusive rights to the presbyopia drop Yuvezzi in the European Union, the UK, Switzerland, Norway, and ...

TearCare Label Expanded to Include Improvement of Meibomian Gland Function

Sight Sciences reported Aug. 19 that the US FDA had expanded the labeling for the TearCare thermal expression device to include improvement of meibomian gland function in adult patients with evapor...

ASRS Meeting Shines Light on Ingenuity of Retina Surgeons Around the Globe

The 2026 annual meeting of the American Society of Retina Specialists (ASRS), held in mid-July at the Palais des Congrès in Montreal, Quebec, opened with a deep dive into surgery. The first day off...

Quarterly Revenue Roundup for Carl Zeiss Meditec and Santen

German company Carl Zeiss Meditec reported Aug. 6 that its ophthalmic device revenue for the three months ended June 2026 (the third quarter of its fiscal 2025/2026 year) was €437.6 million ($499.7...

EyePoint’s Duravyu Misses Primary Visual Acuity Endpoint in Phase III Wet AMD Trial

EyePoint Pharmaceuticals reported Aug. 17 that Duravyu (vorolanib intravitreal insert) missed its primary visual acuity endpoint in topline results from the Phase III LUGANO trial in wet age-relate...

Zeiss Gains US FDA 510(k) Clearance for Clinic 360 Data Management Software

Carl Zeiss Meditec announced Aug. 19 that it had gained 510(k) clearance from the US FDA for its Clinic 360 image and data management software. The clinical analytics dashboard combines diagnostic ...

Researchers Aim to Conquer Jet Lag Using Engineered RPE Cells

Researchers at Rice and Northwestern universities have developed a subcutaneous therapy using engineered retinal pigment epithelial (RPE) cells that they say could help the body adapt more quickly ...

Ophthalmic Market Poised for Steady Growth Amid Digital Shift, Rising Demand

Ophthalmology continues to expand as global demand for eye care rises, digital technology moves deeper into clinical workflows, and manufacturers push new approaches to diagnosis and treatment. The...

AI Funding Boom Reshapes Venture Capital as Ophthalmology Investment Holds Steady

Record venture capital investment in the first half of 2026 was driven by artificial intelligence (AI) mega-rounds, while ophthalmology continued to draw steady investor interest. AI dominated H1-2...

Tarsus Enters Retina Sector with Two Acquisitions that Could Top $1 Billion

Tarsus Pharmaceuticals, maker of Xdemvy drops for Demodex blepharitis, has ventured into the retina sector recently with two acquisitions that could end up topping $1 billion. Tarsus said its deals...

Select US FDA Approvals and Clearances in July 2026

The US FDA’s ophthalmic device division granted clearance to three devices using the 510(k) pathway in July 2026, according to the agency’s database. iHealthscreen received clearance for its iPredi...

PDUFA Dates for Ophthalmic Drug Candidates, August 2026

The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) and Biosimilar User Fee Act (BsUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.

US FDA Approves Outlook’s Lytenava (Bevacizumab) for Wet AMD

Outlook Therapeutics announced July 24 that it had gained US FDA approval for Lytenava (bevacizumab-vikg) to treat wet age-related macular degeneration (AMD). The news comes after years of regulato...

India’s Biocon Launches Aflibercept Biosimilar Yesafili in the US

India’s Biocon Limited announced on Aug. 3 the commercial launch of Yesafili (aflibercept-jbvf), a biosimilar to Eylea 2 mg, in the US. Yesafili was among a flurry of Eylea biosimilars approved by ...

Alcon Drops Development of PowerVision Accommodating Lens

Alcon reported Aug. 10 in its Q2-2026 earnings report that it had discontinued work on the PowerVision FluidVision accommodating IOL, following analysis of the latest clinical study data. Alcon sai...

Want to Read Locked Articles?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.